AstraZeneca's Klygefa Recommended for EU Approval in Rare Muscle Disease

AstraZeneca and Alexion's Klygefa (gefurulimab) received a positive recommendation from the EU's Committee for Medicinal Products for Human Use (CHMP) for generalized myasthenia gravis. This is a regulatory milestone, but final approval and market launch remain pending. The decision is significant for patients with this rare disease and for AstraZeneca's rare-disease portfolio.